This activity is supported by an independent education grant from BMS. This online education program has been designed for healthcare professionals globally, excluding the UK.
Join expert Toby Maher, MD, PhD, for a case-based clinical review on evaluating progressive pulmonary fibrosis (PPF). This session addresses the transition from diagnostic suspicion to actionable care plans, highlighting how structured radiology reporting and shared care decision frameworks eliminate communication gaps across specialties.
This is Module Two of Four. Modules One, Three, and Four can be found here.
Session Highlights
- Utilize serial pulmonary function tests (PFTs) and HRCT imaging to objectively verify 2022 ATS/ERS/JRS/ALAT criteria for progressive pulmonary fibrosis.
- Transition from narrative free-text radiology reports to structured template dashboards that feature automated pattern classifications and action triggers.
- Integrate multidisciplinary team (MDT) consensus views across rheumatology, pulmonology, radiology, pathology, and nursing to refine diagnostic accuracy.
- Operationalize a Shared Care Decision Tree with designated step owners to ensure seamless transition from PPF alerts to treatment initiation.
Target Audience
This activity is intended for pulmonologists, rheumatologists, thoracic radiologists, pathologists, pulmonology nurse practitioners, and physician assistants/associates who are central to the diagnosis and management of IPF and PPF. It is also designed for general practitioners, respiratory therapists, pharmacists, and other multidisciplinary healthcare professionals involved in the care of patients with pulmonary fibrosis.
Faculty
Dr Toby Maher is Professor of Clinical Medicine and Director of Interstitial Lung Disease at the Keck School of Medicine of the University of Southern California. He has dedicated his career to advancing clinical care, education, and research in interstitial lung disease, idiopathic pulmonary fibrosis, and progressive pulmonary fibrosis.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr Toby Maher, faculty for this educational activity, has the following relevant financial relationships: Consultant, Advisor, and Speaker for AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, GSK, Insmed, Merck, and United Therapeutics.
The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-26-362-H01-P
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 30, 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 1 November 2026 through to 30 September 2027.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.
This continuing education activity is active starting 1 November, 2026 and will expire on 30 September, 2027.
Estimated time to complete this activity: 15 Minutes